MLANA and metastatic melanoma: In the subsequent trial, in which 14 patients with metastatic melanoma received 3 adenovirus (AdV)-MART-1-engineered DC vaccines (expressing full length MART-1 and inducing MART-1-specific CD8+ and CD4+ T cells), 3 patients showed evidence of determinant spreading and long overall survival [17].